Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B

146
8
Favorite

Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B

seekingalpha2021-09-08

(Update: Sept 8, 2021 at 04:13 a.m. ET) With an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B. Following completion of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

146

Report

Comment（8）

replaygoh
·2021-09-09
okok
Reply
1
Report
Val準凖
·2021-09-08
Good
Reply
1
Report
ParableTalen
·2021-09-08
This giant. Just buy only.
Reply
3
Report
老Uncle
·2021-09-08
OMG ??
Reply
3
Report
Fold Replies
- 老Uncle:
  ?
  2021-09-08
  Reply
  Report
- 老Uncle:
  fly so much
  2021-09-08
  Reply
  Report
- Grest:
  Omfg
  2021-09-08
  Reply
  Report
View more 1 comments
SSKONG
·2021-09-08
Great ariticle, would you like to share it?
Reply
1
Report
Fish2102
·2021-09-08
Tell me your opinion about this news...
Reply
2
Report
Fish2102
·2021-09-08
Hi guys, i got some KDMN shares. Does thatmeans besides the share price i will get additional $9.50 if i sell the share?
Reply
3
Report
Fold Replies
- 路人丙钉钉:
  看什么价格拿下的吧~如果不看好这家公司，就做个短线，卖掉也不心疼
  2021-09-08
  Reply
  Report
- setia100:
  congrats ???
  2021-09-08
  Reply
  Report
- 时空下流浪:
  感谢恁的无私分享，能在具体地说下吗？为什么会额外所得9.5
  2021-09-08
  Reply
  Report
JPTL
·2021-09-08
?
Reply
2
Report
Fold Replies
- Big__Boss:
  nice
  2021-09-08
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1152225600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-08 15:58","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1152225600","market":"us","top_or_hot":-1,"title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","media":"seekingalpha","content":"<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KDMN","symbol_name":"Kadmon Holdings LLC","start_time":0,"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","article_id":"1152225600","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","pubTimestamp":1631087910,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"translate_title":"赛诺菲以1.9亿美元收购Kadmon，加强移植业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KDMN":0.9,"SNY":0.9},"content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":889866508,"gmtCreate":1631140942604,"gmtModify":1676530475904,"author":{"id":"3582963095283492","authorId":"3582963095283492","name":"replaygoh","avatar":"https://static.tigerbbs.com/d47b21291424a3d55039334a8de5cdb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3582963095283492","idStr":"3582963095283492"},"htmlText":"okok","listText":"okok","text":"okok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889866508","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":889920647,"gmtCreate":1631104967689,"gmtModify":1676530468416,"author":{"id":"3581556348949722","authorId":"3581556348949722","name":"Val準凖","avatar":"https://static.tigerbbs.com/fc78ba8079eaf21b89d9286a3857c533","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3581556348949722","idStr":"3581556348949722"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889920647","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":889065383,"gmtCreate":1631093053542,"gmtModify":1676530465551,"author":{"id":"3580300192386766","authorId":"3580300192386766","name":"ParableTalen","avatar":"https://static.tigerbbs.com/94daa928259bc550d0ee26f23a953bb8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3580300192386766","idStr":"3580300192386766"},"htmlText":"This giant. Just buy only.","listText":"This giant. Just buy only.","text":"This giant. Just buy only.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889065383","repostId":1152225600,"repostType":2,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":889089662,"gmtCreate":1631091370756,"gmtModify":1676530465193,"author":{"id":"3581063216443091","authorId":"3581063216443091","name":"老Uncle","avatar":"https://static.tigerbbs.com/ef0828d104dbb47c9e2122177cf0d3b5","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3581063216443091","idStr":"3581063216443091"},"htmlText":"OMG ??","listText":"OMG ??","text":"OMG ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/889089662","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5792135,"gmtCreate":1631093322715,"gmtModify":1663233558626,"authorId":3581063216443091,"author":{"id":3581063216443091,"idStr":"3581063216443091","authorId":3581063216443091,"name":"老Uncle","avatar":"https://static.tigerbbs.com/ef0828d104dbb47c9e2122177cf0d3b5","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.31%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889089662,"type":1,"supId":5792060,"prevId":0,"content":"?","text":"?","html":"?"},{"id":5792514,"gmtCreate":1631095895529,"gmtModify":1663233558142,"authorId":3581063216443091,"author":{"id":3581063216443091,"idStr":"3581063216443091","authorId":3581063216443091,"name":"老Uncle","avatar":"https://static.tigerbbs.com/ef0828d104dbb47c9e2122177cf0d3b5","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.31%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889089662,"type":1,"supId":5792436,"prevId":0,"content":"fly so much","text":"fly so much","html":"fly so much"},{"id":5792060,"gmtCreate":1631092868491,"gmtModify":1663233556247,"authorId":3581503320247876,"author":{"id":3581503320247876,"idStr":"3581503320247876","authorId":3581503320247876,"name":"Grest","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889089662,"type":1,"supId":0,"prevId":0,"content":"Omfg","text":"Omfg","html":"Omfg"},{"id":5792436,"gmtCreate":1631094996577,"gmtModify":1634805432306,"authorId":4091089381144950,"author":{"id":4091089381144950,"idStr":"4091089381144950","authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889089662,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":889018183,"gmtCreate":1631090626842,"gmtModify":1676530464940,"author":{"id":"3583495200359485","authorId":"3583495200359485","name":"SSKONG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3583495200359485","idStr":"3583495200359485"},"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889018183","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":889010465,"gmtCreate":1631090295957,"gmtModify":1676530464854,"author":{"id":"3586656056593947","authorId":"3586656056593947","name":"Fish2102","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586656056593947","idStr":"3586656056593947"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889010465","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":889010556,"gmtCreate":1631090279275,"gmtModify":1676530464847,"author":{"id":"3586656056593947","authorId":"3586656056593947","name":"Fish2102","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586656056593947","idStr":"3586656056593947"},"htmlText":"Hi guys, i got some KDMN shares. Does thatmeans besides the share price i will get additional $9.50 if i sell the share?","listText":"Hi guys, i got some KDMN shares. Does thatmeans besides the share price i will get additional $9.50 if i sell the share?","text":"Hi guys, i got some KDMN shares. Does thatmeans besides the share price i will get additional $9.50 if i sell the share?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/889010556","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5795556,"gmtCreate":1631113447418,"gmtModify":1663233571239,"authorId":3479274822738867,"author":{"id":3479274822738867,"idStr":"3479274822738867","authorId":3479274822738867,"name":"路人丙钉钉","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889010556,"type":1,"supId":0,"prevId":0,"content":"看什么价格拿下的吧~如果不看好这家公司，就做个短线，卖掉也不心疼","text":"看什么价格拿下的吧~如果不看好这家公司，就做个短线，卖掉也不心疼","html":"看什么价格拿下的吧~如果不看好这家公司，就做个短线，卖掉也不心疼"},{"id":5791961,"gmtCreate":1631092248024,"gmtModify":1634805466728,"authorId":3567852837945728,"author":{"id":3567852837945728,"idStr":"3567852837945728","authorId":3567852837945728,"name":"setia100","avatar":"https://community-static.tradeup.com/news/5d07af59743ad001196b7aca5f1726d7","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889010556,"type":1,"supId":0,"prevId":0,"content":"congrats ???","text":"congrats ???","html":"congrats ???"},{"id":5792016,"gmtCreate":1631092628201,"gmtModify":1631092628201,"authorId":3479274816899540,"author":{"id":3479274816899540,"idStr":"3479274816899540","authorId":3479274816899540,"name":"时空下流浪","avatar":"https://static.laohu8.com/picture188","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889010556,"type":1,"supId":0,"prevId":0,"content":"感谢恁的无私分享，能在具体地说下吗？为什么会额外所得9.5","text":"感谢恁的无私分享，能在具体地说下吗？为什么会额外所得9.5","html":"感谢恁的无私分享，能在具体地说下吗？为什么会额外所得9.5"}],"langContent":"EN"},{"id":889010108,"gmtCreate":1631090268704,"gmtModify":1676530464847,"author":{"id":"3585350696038563","authorId":"3585350696038563","name":"JPTL","avatar":"https://static.tigerbbs.com/6f6dde4c2c1d83e8d80141b547948419","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585350696038563","idStr":"3585350696038563"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/889010108","repostId":1152225600,"repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5791698,"gmtCreate":1631090680433,"gmtModify":1663233552368,"authorId":3570517865216539,"author":{"id":3570517865216539,"idStr":"3570517865216539","authorId":3570517865216539,"name":"Big__Boss","avatar":"https://static.tigerbbs.com/2c36c2fe68f671064d7d1fd9b7268165","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.03","exceedPercentage":"93.97%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":889010108,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":146,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}